Quick Answer
Centessa Pharmaceuticals plc reported Stockholders Equity of $526.86 million for the year ending 2025.
- Centessa Pharmaceuticals plc showed an increase of +31.2% in Stockholders Equity from 2024 to 2025.
- This data is from Centessa Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2021 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $278.63 million | Q2 2021: $585.64 million | Q3 2021: $549.13 million | Q1 2022: $480.15 million | Q2 2022: $420.04 million | Q3 2022: $372.92 million | Q1 2023: $293.26 million | Q2 2023: $276.61 million | Q3 2023: $259.39 million | Q1 2024: $215.16 million | Q2 2024: $286.97 million | Q3 2024: $499.14 million | Q1 2025: $386.25 million | Q2 2025: $344.92 million | Q3 2025: $301.57 million.
- Over the full 6 years of available data (2021 to 2025), Centessa Pharmaceuticals plc's Stockholders Equity has grown by 11,428.0%.
- Historical annual values: Fiscal year 2025: $526.86 million | Fiscal year 2024: $401.55 million | Fiscal year 2023: $236.24 million | Fiscal year 2022: $336.17 million | Fiscal year 2021: $491.55 million | Fiscal year 2021: -$4.65 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: